Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study.
Gianluca AvalloneFrancesco CavalloAnnalisa TancrediCarlo Alberto MaroneseMartina BertelloAlessandro FraghìConforti ClaudioGiulia CalabreseMatteo R Di NicolaGiorgio A OddeninoLuigi GargiuloNiccolò GoriCamilla LoiPaolo RomitaViviana PirasLaura BonzanoErsilia TolinoGiovanni PaolinoMaddalena NapolitanoCataldo PatrunoEustachio NettisCaterina FerreliGabriele RoccuzzoLuca MarozioMartina SilvioFilomena RussoLuca BettoliniRosella GalloSanto R MercuriLuca MastorinoMariateresa RossiIris ZalaudekGiuseppe ArgenzianoIlaria TraveAntonio CostanzoAndrea ChiricozziCarlotta GurioliCaterina FotiConcetta PotenzaSilvia M FerrucciAnna BalatoAurora ParodiAngelo Valerio MarzanoMichela OrtoncelliSimone RiberoPietro QuaglinoPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
This cohort of pregnant patients exposed to dupilumab adds to the existing evidence concerning the safety of biologic agents in pregnancy. No safety issues were identified regarding the primary outcome assessed. In clinical practice, these data provide reassurance in case of dupilumab exposure during the first trimester. However, the continuous use of dupilumab throughout pregnancy warrants further research.